Enhanced Sensitivity to Tirapazamine and RSU 1069 through P450 Reductase Overexpression
Author Information
Author(s): AV Patterson, MP Saunders, EC Chinje, DC Talbot, AL Harris, IJ Strafford
Primary Institution: Medical Research Council, Harwell, Didcot, Oxon OX11 ORD, UK
Hypothesis
Does overexpression of P450 reductase increase sensitivity to the bioreductive drugs tirapazamine and RSU 1069 in breast cancer cells?
Conclusion
The study found that breast cancer cells with higher P450 reductase activity showed increased sensitivity to tirapazamine and RSU 1069, especially under hypoxic conditions.
Supporting Evidence
- Transfected clones showed up to a 53-fold increase in P450 reductase activity.
- Activity of P450 reductase correlated with both hypoxic and aerobic toxicity of tirapazamine.
- Measurable P450 reductase activity was found in 14 primary human breast tumors.
Takeaway
If certain breast cancer cells have more of a specific protein, they can be hurt more by certain medicines when there's less oxygen around.
Methodology
The study involved transfecting the MDA231 breast cancer cell line with human P450 reductase cDNA and assessing drug sensitivity and enzyme activity.
Limitations
The study primarily focused on a limited number of cell lines and may not fully represent all breast cancer types.
Participant Demographics
Human breast cancer cell lines were used, specifically the MDA231 line.
Statistical Information
P-Value
0.003
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website